All In Biotech

NDA 018251 · Otsuka Icu Medcl

Ringer'S In Plastic Container

Calcium Chloride, Potassium Chloride, Sodium Chloride · Injection

Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1980

May 16, 1980

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

119

114 serious, 20 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 20, 2026.

Ringer's Injection is indicated for use as a source of water and electrolytes in adults and pediatric patients. Ringer's Injection is indicated for use as a source of water and electrolytes in adults and pediatric patients. ( 1 )

Mechanism: Ringer's Injection is a source of water, and electrolytes. Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid. Potassium, the principal cation of intracellular fluid, participates in carbohydrate utilization and protein synthesis and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart. Chloride, the major extracellular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 16, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • RINGER'S IN PLASTIC CONTAINER · CALCIUM CHLORIDE 33MG/100ML; POTASSIUM CHLORIDE 30MG/100ML; SODIUM CHLORIDE 860MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension15
  • pyrexia10
  • dyspnoea8
  • loss of consciousness8
  • stevens-johnson syndrome7
  • bradycardia6
  • cardiac arrest6
  • nausea6
  • renal failure acute6
  • oxygen saturation decreased5
  • toxic epidermal necrolysis5
  • agitation4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200517
20069
20078
200822
200910
201012
20117
20124
20132
20141
20156
20165
20177
20191
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.